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Background: The addition of splenectomy to a D2 gastrectomy in patients with gastric adenocarcinoma
(GA) has remained controversial. This study aimed to assess the impact of splenectomy on the overall
survival of patients undergoing total gastrectomy for GA.
Methods: This was a retrospective review of 463 GA patients (excluding positive resection margins and
pathologic spleen invasion) undergoing curative total gastrectomy with (TS) and without splenectomy
(T) between 1994 and 2008. Clinicopathologic factors affecting the prognosis of these patients were
collected prospectively and analyzed.
Results: Two hundred and ninety one patients had T and 172 patients underwent TS. Patient clinico-
pathological characteristics were comparable between the 2 groups except for tumor size. There were no
signiﬁcant differences in postoperative morbidity and mortality between T and TS groups. Patients in the
T group had similar 3- and 5-year survival rates compared with those in the TS groups (p ¼ 0.181). The
addition of splenectomy to a total gastrectomy did not impact on the overall survival rates in patients
with GA in terms of depth of tumor invasion and nodal metastasis.
Conclusions: The addition of splenectomy is not associated with survival advantage in GA patients un-
dergoing total gastrectomy.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Gastric adenocarcinoma (GA) is the second commonest cause of
cancer-related deaths worldwide. [1] Currently, radical gastric
resection with adequate lymphadenectomy in patients with GA
provides the best chance of cure [2]. Lymph node metastasis is onergery, Chang Gung Memorial
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tive resection [3e5]. The rate of metastasis to the lymph nodes at
the splenic hilum (no. 10) in patients with proximal gastric cancer
ranges from 9% to 28% [6e8]. The 5-year survival rate was only 11%
for patients with splenic hilar node involvement, which was
signiﬁcantly worse than the rate of 52% in those without splenic
hilar node metastasis [6]. Splenic lymph node involvement has not
been observed in early GA [6]. Given the fact that the survival
beneﬁt of splenectomy is uncertain and the associated morbidity
and mortality rates are not insigniﬁcant, performing a splenectomy
for the purpose of splenic hilar node clearance is only advocated in
patients with high suspicion of metastasis near the splenic hilum or
direct tumor invasion of the spleen [6,7,9,10]. Although there are
prospective randomized and retrospective trials reporting no sur-
vival beneﬁt on the impact of splenectomy on the long-term sur-
vival of GA patients, the sample sizes in these studies are small.
Table 1
Clinicopathological characteristics of patients with gastric adenocarcinoma undergoing total gastrectomy with or without splenectomy.
Parameters Non-splenectomy N ¼ 291 Splenectomy N ¼ 172 P
Age (years) 0.471
Median (range) 65 (53e73) 66 (56e73)
Gender 0.456
Male 195 121
Female 96 51
Tumor size (cm) 0.040
Median (range) 5.0 (3.3e7.0) 5.5 (3.5e8.0)
Differentiation 0.387
Yes 105 69
No 186 103
Location 0.145
Lesser curvature 163 83
Greater curvature 25 20
Whole 30 28
Other 73 41
T status 0.459
T1 þ T2 26 19
T3 þ T4 265 153
N status 0.395
N0 83 44
N1 48 28
N2 46 38
N3 114 62
LN ratioa 0.171
Median (range) 0.1 (0.0e0.4) 0.2 (0.0e0.4)
No. of examined lymph node 0.148
15 41 33
>15 250 139
No. of examined lymph node 0.171
Median (range) 29.0 (21.0e40.0) 26.0 (18.0e36.0)
No. of lymph node metastasis 0.469
Median (range) 3.0 (0.0e11.0) 4.0 (0.0e10.8)
Stage 0.682
I 22 14
II 64 32
III 205 126
Vascular invasion (yes) 48 37 0.163
Lymphatic invasion (yes) 171 111 0.171
Perineural invasion (yes) 168 100 0.855
Comorbidity 0.761
0 200 123
1 65 38
2 17 8
3 9 3
Charlson comorbidity index score 0.339
2 181 109
3 89 52
4 20 8
5 1 3
Complications 61 37 0.889
Surgical procedure-related
Anastomotic leak 21 20 0.106
Intra-abdominal abscess 15 8 0.810
Wound infection 10 9 0.347
Bleeding 4 6 0.184
Ileus 4 0 0.302
Surgical procedure-unrelated
Pneumonia 6 4 1.000
Atelectasis 1 0 1.000
Cardiovascular disease 3 0 0.298
Sepsis 4 0 0.302
Others 17 7 0.406
Hospital mortality 14 7 0.711
Chemotherapyb(yes) 192 102 0.158
a Ratio of metastatic to examined lymph nodes.
b Excluding T1-2N0 cases.
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Fig. 1. Cumulative overall survival rates in T1e2 (A) and T3e4 (B) lesion with and without splenectomy.
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Fig. 2. Cumulative overall survival rates in N0-2 (A) and N3 (B) lesion with and without splenectomy.
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Table 2
Univariate and multivariate analyses of prognostic factors in patients with gastric adenocarcinoma undergoing total gastrectomy with or without splenectomy.
Factors Hazard ratio 95% CI P Hazard ratio 95% CI P
Age 0.586
65 (n ¼ 220) 1.079 0.821e1.419
>65 (n ¼ 222) 1
Gender 0.469
Male (n ¼ 303) 1
Female (n ¼ 139) 1.115 0.830e1.498
Tumor size (cm)a <0.001
5 (n ¼ 223) 1 1
>5 (n ¼ 210) 2.710 2.043e3.595 1.447 1.049e1.995 0.024
Differentiation <0.001
Yes (n ¼ 168) 1 1
No (n ¼ 274) 2.065 1.567e2.722 1.466 1.045e2.055 0.027
Location <0.001
Lesser curvature (n ¼ 232) 1 1
Greater curvature (n ¼ 43) 1.976 1.184e3.298 1.522 0.968e2.395 0.069
Whole (n ¼ 56) 5.607 3.248e9.679 2.647 1.759e3.984 <0.001
Others (n ¼ 111) 1.106 0.774e1.579 1.358 0.941e1.959 0.102
T status <0.001
1 þ 2 (n ¼ 44) 1 1
3 þ 4 (n ¼ 398) 2.914 1.941e4.374 5.883 1.436e24.102 0.014
Nodal status <0.001
N0 (n ¼ 126) 1 1
N1 (n ¼ 69) 3.906 2.096e7.279 2.226 1.105e4.483 0.025
N2 (n ¼ 80) 5.957 3.473e10.220 2.206 1.008e4.827 0.048
N3 (n ¼ 167) 6.303 4.444e8.941 2.571 1.118e5.908 0.026
LN ratiob <0.001
0.14 (n ¼ 217) 1 1
>0.14 (n ¼ 225) 4.772 3.594e6.335 1.858 1.077e3.206 0.026
Vascular invasiona <0.001
No (n ¼ 349) 1 1
Yes (n ¼ 82) 2.165 1.524e3.076 1.399 1.002e1.953 0.049
Lymphatic invasiona <0.001
No (n ¼ 164) 1 1
Yes (n ¼ 267) 3.435 2.595e4.546 1.120 0.685e1.829 0.651
Perineural invasiona <0.001
No (n ¼ 174) 1 1
Yes (n ¼ 254) 2.179 1.646e2.884 1.858 1.077e2.206 0.058
Splenectomy 0.181
No (n ¼ 277) 1
Yes (n ¼ 165) 1.214 0.914e1.611
Chemotherapyc 0.171
No (n ¼ 113) 1.254 0.907e1.734
Yes (n ¼ 294) 1
CI, Conﬁdence interval.
a Not all data were available.
b Ratio of metastatic to examined lymph nodes.
c Excluding T1e2N0M0 cases.
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niﬁcance of splenectomy in a large cohort of GA patients under-
going total gastrectomy.
2. Patients and methods
2.1. Ethics statement
This study was reviewed and approved by the institutional re-
view board of Chang Gung Memorial Hospital (No.: 99-2698B).
Written informed consent was obtained from all patients. All data
were stored in the hospital database and used for research.
2.2. Patients
Three thousand two hundred and six consecutive patients with
GA underwent a gastrectomy between 1994 and 2008 at Chang
Gung Memorial Hospital in Linkou, Taoyuan, Taiwan. Excluding
patients who had a subtotal gastrectomy, previous partial gastrec-
tomy, palliative resection or positive resection margins andpathologic splenic or pancreatic invasion, 463 patients undergoing
total gastrectomy were enrolled into this study. The standard pro-
cedure included a pancreas-preserving D1 or D2 lymph node
dissection depending on the perceived degree of tumor invasion
and lymph node metastasis. Resection of other adjacent organs was
undertaken, if necessary, to achieve a negative surgical margin [13].
Spleen-preserving total gastrectomy would be preferentially per-
formed except in tumor locating at the greater curvature near the
spleen, large tumor size (>5 cm), gross tumor invasion of or
adhesion to the splenic hilum, and signiﬁcant splenic hilar
lymphadenopathy. No patient received neoadjuvant chemotherapy
or postoperative radiotherapy. Patients with stage IIeIII GA
received postoperative adjuvant ﬂuoropyrimidine or platinum-
based chemotherapy. The treatment duration usually lasts for
about 6 months.
The clinicopathological parameters such as gender, age,
comorbidities, Charlson comorbidity index score [14], tumor size,
tumor differentiation, tumor location, depth of tumor invasion,
nodal status, numbers of examined lymph nodes, tumor staging,
presence of vascular, lymphatic, and perineural invasion,
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were compared between patients undergoing a total gastrectomy
with (TS) or without (T) splenectomy. Tumors were staged ac-
cording to the seventh edition of the American Joint Committee on
Cancer Staging System [15].2.3. Statistical analysis
Continuous data were presented as median and ranges. Clinical
variables were compared using Student’s t-test or Pearson’s chi-
square test as appropriate. Overall survival (OS) was calculated
from the date of surgery to death, date of the last follow-up or 31st
December, 2009. Survival duration was estimated by the Kaplane
Meier methods after excluding in-hospital deaths. The differences
in survival distributionwere assessed bymeans of the log-rank test.
Factors with P < 0.05 were included in the multivariate analysis.
The ﬁnal multivariate model was determined using Cox propor-
tional hazard regression in order to identify independent predictors
of OS. P value < 0.05 was considered statistically signiﬁcant. All
statistical analyses were performed using the Statistical Package for
the Social Sciences version 13 (SPSS Inc., Chicago, IL, USA) and Prism
5.0 (GraphPad Software, San Diego, USA) for Windows.Table 3
Univariate and multivariate analyses of prognostic factors in patients with gastric adeno
Factors Hazard ratio 95% CI
Age
65 (n ¼ 77) 1.033 0.674e1.582
>65 (n ¼ 88) 1
Gender
Male (n ¼ 118) 1
Female (n ¼ 47) 0.965 0.603e1.543
Tumor size (cm)a
5 (n ¼ 76) 1
>5 (n ¼ 84) 3.195 2.060e4.957
Differentiation
Yes (n ¼ 68) 1
No (n ¼ 97) 2.314 1.510e3.546
Location
Lesser curvature (n ¼ 78) 1
Greater curvature (n ¼ 19) 1.109 0.631e1.949
Whole (n ¼ 27) 3.889 1.891e7.999
Others (n ¼ 41) 1.092 0.533e2.237
T status
1 þ 2 (n ¼ 19) 1
3 þ 4 (n ¼ 146) 2.621 1.413e4.860
Nodal status
N0 (n ¼ 44) 1
N1 (n ¼ 27) 4.293 1.613e11.430
N2 (n ¼ 35) 6.409 2.899e14.170
N3 (n ¼ 59) 6.954 3.956e12.220
LN ratiob
0.17 (n ¼ 84) 1
>0.17 (n ¼ 81) 4.542 2.907e7.096
Vascular invasiona
No (n ¼ 123) 1
Yes (n ¼ 37) 2.558 1.488e4.398
Lymphatic invasiona
No (n ¼ 54) 1
Yes (n ¼ 106) 3.656 2.345e5.700
Perineural invasiona
No (n ¼ 62) 1
Yes (n ¼ 97) 2.332 1.501e3.624
Chemotherapyc
No (n ¼ 49) 1.063 0.662e1.708
Yes (n ¼ 102) 1
CI, Conﬁdence interval.
a Not all data were available.
b Ratio of metastatic to examined lymph nodes.
c Excluding T1e2N0M0 cases.3. Results
The clinicopathological features of the 463 patients with GA
undergoing T or TS are summarized in Table 1. There were no sig-
niﬁcant differences between the 2 groups in terms of clinicopath-
ologic characteristics (except for tumor size), comorbidity, Charlson
comorbidity index score, postoperative complications and in-
hospital mortality rates. Two hundred and ninety-four patients
received chemotherapy and 113 did not. The percentages of pa-
tients receiving adjuvant chemotherapy were similar between the
2 groups after excluding patients with T1-2N0 disease.3.1. Survival
The follow-up rates were 90% and 88% in the TS and T groups,
respectively. After amedian follow-up of 27.6months, the overall 3-
and 5-year survival rates were 59% and 51%, respectively, for the T
group, and 51% and 47%, respectively, in the TS group (p ¼ 0.181).
Therewere no statistically signiﬁcant differences in the OS between
the T and TS groups with respect to the depth of tumor invasion
(Fig. 1A and B) and lymph node metastasis (Fig. 2A and B).carcinoma undergoing total gastrectomy and splenectomy.
P Hazard ratio 95% CI P
0.882
0.881
<0.001
1
1.591 0.909e2.784 0.104
<0.001
1
1.495 0.837e2.670 0.174
0.001
1
1.172 0.520e2.643 0.702
2.627 1.411e4.891 0.002
1.443 0.794e2.625 0.229
0.002
1
2.765 0.625e12.233 0.180
<0.001
1
3.319 0.946e11.647 0.061
6.249 1.492e26.170 0.012
6.223 1.399e27.678 0.016
<0.001
1
1.254 0.556e2.832 0.586
0.001
1
1.078 0.648e1.794 0.773
<0.001
1
1.127 0.423e3.000 0.812
<0.001
1
1.418 0.792e2.540 0.240
0.800
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4.1. All patients
As shown in Table 2, factors potentially related to OS in the
univariate analysis were: tumor size >5 cm, tumor differentiation,
tumor location, depth of tumor invasion, nodal status, ratio of
metastatic to examined lymph nodes, and presence of vascular,
lymphatic or perineural invasion. Splenectomy was not prognostic
of survival. Multivariate model identiﬁed tumor size >5 cm [(haz-
ard ratio (HR) 1.447, 95% conﬁdence interval (CI) 1.049e1.995,
p¼ 0.024)], tumor dedifferentiation (HR 1.466, 95% CI 1.045e2.055,
p¼ 0.027), tumor location (whole versus lesser curvature, HR 2.647,
95% CI 1.759e3.984, p < 0.001), T stage (T3 þ 4 versus T1 þ 2, HR
5.883, 95% CI 1.436e24.102, p ¼ 0.014), N stage (N1 versus N0, HR
2.226, 95% CI 1.105e4.483, p ¼ 0.025; N2 versus N0, HR 2.206, 95%
CI 1.008e4.827, p ¼ 0.048; N3 versus N0, HR 2.571, 95% CI 1.118e
5.908, p ¼ 0.026), ratio of metastatic to examined lymph nodes
>0.14 (HR 1.858, 95% CI 1.077e3.206, p ¼ 0.026), and vascular in-
vasion (HR 1.399, 95% CI 1.002e1.953, p ¼ 0.049) as the indepen-
dent predictors of OS.
4.2. Patients in the total gastrectomy and splenectomy group
In patients undergoing TS, tumor location (whole versus lesser
curvature, HR2.627, 95% CI 1.411e4.891, p ¼ 0.002) and nodal me-
tastases (N2 versus N0, HR 6.249, 95% CI 1.492e26.170, P ¼ 0.012;
N3 versus N0, HR 6.223, 95% CI 1.399e27.678, p ¼ 0.016) were
independently prognostic of OS in themultivariate model (Table 3).
5. Discussion
Total gastrectomy and D2 lymphadenectomy (including splenic
hilar lymph nodes) has long been the standard procedure in the
Asian countries in patients with advanced proximal GA. The
adoption of D2 lymphadenectomy in the Western population was
low initially and this was mainly due to concerns regarding the
signiﬁcant increase in the postoperative morbidity and mortality in
comparison with D1 lymphadenectomy [16,17]. However, most of
the postoperative complications and mortality were attributable to
the addition of distal pancreatectomy and splenectomy to the
gastrectomy [7,18]. Whilst pancreatectomy is no longer advocated
in the absence of direct tumor involvement, the role of splenectomy
has remained controversial. Preoperative and intraoperative diag-
nosis of nodal metastasis in the splenic hilum is often difﬁcult. As a
result, resection of the spleen has been recommended by some
authors to facilitate complete clearance of the splenic hilar lymph
nodes, thereby achieving local control [19e22]. It is interesting to
note that, while some studies have demonstrated an increase, albeit
small, in the number of lymph nodes harvested with splenectomy
in comparison with splenic preservation D2 gastrectomy, Yu et al.
[9] and our study had comparable numbers of dissected lymph
nodes between the T and TS groups, suggesting that adequate
regional lymph node dissection can be achieved without sacriﬁcing
the spleen [23]. The frequency of splenic hilar lymph node metas-
tasis is associated with tumor stage, tumor location and nodal
status [6,8,24,25]. Although the reported incidence of splenic hilar
lymph node metastasis ranges from 9% to 28%, none has been
demonstrated in patients with early GA [6,8,24,25]. This observa-
tion would indicate that prophylactic splenectomy in patients with
early GA is unnecessary.
The impact of splenectomy on the long-term survival of patients
with GA is unclear, with various retrospective studies reporting
conﬂicting results. Ikeguchi et al. [26] demonstrated similar sur-
vival outcomes between patients with positive no. 10 lymph nodesand those without no. 10 metastasis. Splenectomy was an inde-
pendent prognostic factor in patients with advanced GA and no. 10
lymph node metastasis who underwent D2 resection and concur-
rent splenectomy [27]. However, other authors had failed to
observe any survival advantage with splenectomy [6,23,28e31].
Furthermore, Zhu et al. [8] questioned the utility of splenectomy in
patients at high risk of positive no. 10 lymph nodes, as the presence
of splenic hilar node metastasis was one of the independent pre-
dictors of distant metastasis and the survival outcomes for this
group of patients after R0 resection was not signiﬁcantly different
from those who had R1-2 resection. In our study, the 3- and 5-year
survival rates did not differ between T and TS groups and the sur-
vival estimates were also comparable in the two groups stratiﬁed
according to depth of tumor invasion (Fig. 1) and nodal status
(Fig. 2). Two recent randomized controlled trials and 1 meta-
analysis of D2 total gastrectomy and splenectomy had found no
signiﬁcant difference in the OS [9,21,32]. Yu et al. [9] showed a non
signiﬁcant improvement in the 5-year survival in the splenectomy
group and no signiﬁcant survival beneﬁt in patients withmetastatic
lymph nodes at the splenic hilum or along the splenic artery.
Csendes et al. [32] also failed to observe any statistically signiﬁcant
difference in the 5-year survival rates between the total gastrec-
tomy and total gastrectomy plus splenectomy groups. A meta-
analysis that included these 2 studies, in fact, demonstrated a
non signiﬁcant trend towards better 5 year overall survival in favor
of the splenectomy group. Similar ﬁnding was observed when the
survival rates were stratiﬁed by proximal and whole gastric cancer
[21]. However, it was noted by the authors that the sample size in
these RCTs was far too small, and a well-designed RCT is needed to
explore the effectiveness of splenectomy, especially for proximal
and whole gastric cancer. As a result, a large, multicenter, ran-
domized controlled trial with 505 patients examining the inﬂuence
of splenectomy on the proximal GA of T2e4/N0-2/M0 has been
conducted to overcome this deﬁciency in the previous studies, and
the long term survival outcome is awaited [33].
Studies have observed higher morbidity rates, particularly in-
fectious complications, in patients undergoing concurrent sple-
nectomy than those without [32,34,35]. Splenectomy has also been
shown to be an independent factor inﬂuencing postoperative
complications [28,34,36,37]. Surgical complications are known to
adversely impact on long-term survival in patients with GA [38,39].
Hartgrink et al. [16] concluded in their study that the relevance of
clearing lymph nodes around the splenic hilum has to be ques-
tioned as the survival beneﬁt was small and the associated
morbidity and mortality were markedly increased. The post-
operativemorbidity rateswere similar between the Tand TS groups
in the present study, and had no signiﬁcant impact on the long-
term outcomes in GA patients.
Nodal status has been consistently shown to be one of the
important prognostic factors in patients undergoing curative gas-
trectomy for GA, including the present study [3e5,11]. While the 5-
year survival rates were 64% and 67%, respectively, in N0-2 patients
undergoing D2 total gastrectomy with or without splenectomy, the
survival rates dropped sharply to 16% and 24%, respectively, in N3
disease. Splenectomy itself does not seem to be effective in patients
with advanced nodal disease. The dismal prognosis in N3 disease
suggests that more effective adjuvant therapies are needed to
improve survival outcomes in this group of patients.
The main limitation of the present study is that we did not
speciﬁcally separate the removed lymph nodes into their respective
anatomical stations according to the Japanese Classiﬁcation of
Gastric Cancer [40]. Consequently, it is difﬁcult to comment on the
pattern of locoregional lymph node spread and prognostic signiﬁ-
cance of lymph node metastasis at the splenic hilum and along the
distal splenic artery.
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There is no association between performing a total gastrectomy
with a splenectomy and the overall survival in GA patients. Sple-
nectomy is, therefore, not recommended in absence of direct tumor
invasion of the spleen or signiﬁcant lymphadenopathy at the
splenic hilum.
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